STOCK TITAN

Bolt Biotherapeutics (BOLT) Stock News, Nov 2022-May 2023

BOLT NASDAQ

Bolt Biotherapeutics develops cancer immunotherapies using its Boltbody™ Immune-Stimulating Antibody Conjugate platform and myeloid-biology programs. Company updates focus on BDC-4182, a next-generation claudin 18.2 ISAC clinical candidate for gastric and gastroesophageal cancers, along with BDC-3042, a Dectin-2 agonist antibody, and preclinical ISAC programs targeting CEA and PD-L1.

Recurring news also includes clinical and preclinical data presentations, quarterly financial results, cash runway commentary, collaboration activity with Genmab and Toray, partnering process disclosures for pipeline assets, conference participation, and cost-control actions tied to the company’s oncology research and development strategy.

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.50%
Tags
-
Rhea-AI Summary

Bolt Biotherapeutics (Nasdaq: BOLT) announced the presentation of comprehensive Phase 1 data for BDC-1001 at the 2023 ASCO Annual Meeting, highlighting its potential as a treatment for HER2-expressing cancers. The Phase 1 trial, which included over 100 patients, demonstrated favorable safety and efficacy results, supporting the recommended Phase 2 dose and schedule. The company plans to initiate two Phase 2 trials in 2023: one evaluating BDC-1001 as a monotherapy for HER2-positive solid tumors and another in combination with nivolumab and pertuzumab. The ASCO presentation will take place on June 3, 2023. BDC-1001 is designed to enhance immune response against tumors via a novel immune-stimulating antibody conjugate mechanism.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.25%
Tags
conferences clinical trial
-
Rhea-AI Summary

Bolt Biotherapeutics announced promising topline data from its Phase 1 clinical study of BDC-1001, validating its Boltbody™ ISAC platform's anti-tumor activity and safety. The company is set to launch a focused Phase 2 program in 2023, exploring BDC-1001 both as a monotherapy and in combination with nivolumab in several cancers, including colorectal, endometrial, and gastroesophageal. Additionally, BDC-3042 is expected to enter the clinic this year. With a strong cash position of $192.8 million, Bolt anticipates funding its key milestones through 2025. Collaboration revenues rose, with significant contributions from Genmab and Innovent.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.88%
Tags
Rhea-AI Summary

Bolt Biotherapeutics (Nasdaq: BOLT) announced positive topline data from its Phase 1 dose-escalation study of BDC-1001, a HER2-targeting Immune-Stimulating Antibody Conjugate. Results showed objective clinical responses, including multiple partial responses (PRs) and long-term stable disease across various solid tumor types when administered alone and with nivolumab. The company plans to advance BDC-1001 into Phase 2 studies focusing on breast, colorectal, endometrial, and gastroesophageal cancers. Additionally, a collaboration with Roche will supply pertuzumab (Perjeta®) for further investigations, highlighting the ongoing commitment to developing innovative cancer therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.88%
Tags
-
Rhea-AI Summary

Bolt Biotherapeutics (Nasdaq: BOLT) announced plans to present new preclinical data for BDC-3042, an agonistic antibody targeting Dectin-2, at the AACR Annual Meeting 2023 from April 14-19. The data highlights BDC-3042's mechanism of action in reprogramming tumor-associated macrophages (TAMs) to enhance anti-tumor immunity. Key findings include strong binding to TAMs, pro-inflammatory cytokine production, and tumor growth inhibition in humanized mouse models. Bolt aims to move BDC-3042 into clinical trials this year, emphasizing its potential across various cancers. The presentation details will be available post-conference on Bolt’s website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.31%
Tags
conferences clinical trial
-
Rhea-AI Summary

Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company focusing on
immuno-oncology therapeutics for cancer treatment, announced its management will present at the
Cowen 43rd Annual Healthcare Conference on March 7, 2023, at 2:50 p.m. EST in Boston, Mass. A live webcast
of the presentation will be accessible on Bolt's website, with archived replays available for 30 days.
The company is advancing its drug pipeline, including BDC-1001 for HER2-expressing tumors and BDC-3042, targeting Dectin-2.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.26%
Tags
conferences
Rhea-AI Summary

Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company, announced its participation in two key conferences in February 2023. Management will engage in a fireside chat at the Guggenheim Healthcare Talks 2023 Oncology Day on February 8 at 12:55 p.m. PST, followed by another chat at the Virtual SVB Securities Global Biopharma Conference 2023 on February 16 at 12:40 p.m. PST. Live webcasts of these events will be available on Bolt's website, with archived replays accessible for 30 days post-event. The company specializes in developing novel immunotherapies for cancer treatment, with a focus on its pipeline candidates, including BDC-1001 and BDC-3042.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
conferences
-
Rhea-AI Summary

Bolt Biotherapeutics, Inc. (Nasdaq: BOLT) has appointed Laura Berner to its Board of Directors as of December 14, 2022. Laura brings extensive experience in biopharmaceuticals, having executed over 50 transactions in her career. Her strategic insights are expected to support Bolt's ongoing development of its immunotherapy pipeline, particularly BDC-1001, which is advancing into Phase 2 clinical trials, and BDC-3042, slated for clinical evaluation. CEO Randall Schatzman expressed enthusiasm for her contributions, highlighting her potential to enhance Bolt's commitment to cancer treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.94%
Tags
management
-
Rhea-AI Summary

Bolt Biotherapeutics (BOLT) reported third-quarter 2022 results, highlighting the dose-escalation trials for BDC-1001 targeting HER2-expressing tumors, with recruitment on track for completion by year-end 2022. Collaboration revenue rose to $2.1 million, a 50% increase from the previous quarter. R&D expenses remained stable at $19.0 million, while G&A expenses increased to $5.5 million. The company’s cash balance stands at $209.6 million, expected to fund operations through 2025. Upcoming milestones include topline data from BDC-1001 and the initiation of BDC-3042 clinical studies in 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.10%
Tags
Rhea-AI Summary

Bolt Biotherapeutics, Inc. (Nasdaq: BOLT) presented new preclinical data on BDC-3042, a Dectin-2 targeting agonistic antibody, at the 2022 SITC Annual Meeting in Boston. The innovative therapy aims to convert immunosuppressive tumor-associated macrophages into immunostimulatory cells, potentially enhancing anti-tumor immunity. Key findings include BDC-3042's ability to selectively activate these macrophages, thereby facilitating anti-tumor activity in preclinical models. Bolt is advancing BDC-3042 through IND-enabling studies as part of its commitment to developing novel cancer immunotherapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.75%
Tags
conferences clinical trial

FAQ

What is the current stock price of Bolt Biotherapeutics (BOLT)?

Bolt Biotherapeutics (BOLT) last closed at $5.65.

What is the market cap of Bolt Biotherapeutics (BOLT)?

The market cap of Bolt Biotherapeutics (BOLT) is approximately $14.7M.